This subproject represents an estimate of the percentage of the CTSA funding that is being utilized for a broad area of research (AIDS research, pediatric research, or clinical trials). The Total Cost listed is only an estimate of the amount of CTSA infrastructure going towards this area of research, not direct funding provided by the NCRR grant to the subproject or subproject staff. The University of Michigan Clinical and Translational Sciences Award (UM CTSA) will focus the formidable strengths of one of the world's finest research institutions on supporting and facilitating clinical and translational """"""""team science"""""""". The UM CTSA will be housed in the newly created Michigan Institute of Clinical and Health Research (MICHR). MICHR was created by the University to maximize the potential of an institution that is extremely supportive of interdisciplinary research and has tremendous strengths in the health sciences. MICHR creates a partnership between relevant unit of the University, the NIH, external industry partners, and the community. The overwhelming majority of UM schools, colleges, and institutes are participating, including the top-ranked Schools of Business, Dentistry, Medicine, Nursing, Social Work, and Public Health, the Colleges of Engineering, Pharmacy, and Literature, Science and Arts, the Division of Kinesiology, the Institute of Social Research, and the Life Sciences Institute. The University-owned Health System, which includes integrated outpatient and inpatient facilities, is contributing significantly to a strong partnership with the UM CTSA. The Director of MICHR is the PI of the UM CTSA grant, and reports to a University Executive Vice President, who also oversees the Medical School and Health System. In addition to the grant resources, the institution is contributing nearly $11 million/vr of in-kind support, cost-sharing, support of pilot and recruitment programs, and renovation costs, a more than 1:1 match of NIH dollars. Blue Cross Blue Shield of Michigan and Pfizer are also making sizable investments. Departments are also contributing more than 100 FTE in potential faculty effort, so that MICHR can grant effort for pilot studies, K- 12, and new """"""""mini-K programs"""""""". These aggregate resources are used to create robust infrastructure and support based on strong existing units and programs, as well as academic programs in key clinical and translational disciplines, to provide faculty leadership, expertise, and consultation as well as high quality services. These Programs are in Biomedical Informatics, Biostatistics, Clinical Translation, Novel Methods, Technical Cores, Community Engagement, Ethics, Health Disparities, Pediatrics, and Regulatory Support. A radically reconfigured Participant and Clinical Interactions Resource is also described. These programs are all united by an Education Program that reaches a wide spectrum of audiences: from undergraduates to mid-career faculty, from basic scientists to population researchers, from staff to community members. Both accelerated options and intensive programs are available. Finally, a robust pilot program will disburse up to $8 million/yr in pilot funds, focusing on stimulating translational and interdisciplinary studies.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
5UL1RR024986-05
Application #
8365216
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Project Start
2011-06-01
Project End
2012-06-26
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
5
Fiscal Year
2011
Total Cost
$7,237,879
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Pediatrics
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Peciña, Marta; Sikora, Magdalena; Avery, Erich T et al. (2017) Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response. Eur Neuropsychopharmacol 27:977-986
Di Bisceglie, A M; Lombardero, M; Teckman, J et al. (2017) Determination of hepatitis B phenotype using biochemical and serological markers. J Viral Hepat 24:320-329
Saito, Toshie; Miyagawa, Kazuya; Chen, Shih-Yu et al. (2017) Upregulation of Human Endogenous Retrovirus-K Is Linked to Immunity and Inflammation in Pulmonary Arterial Hypertension. Circulation 136:1920-1935
Chen, Jing; Budoff, Matthew J; Reilly, Muredach P et al. (2017) Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease. JAMA Cardiol 2:635-643
Hayashi, Paul H; Rockey, Don C; Fontana, Robert J et al. (2017) Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology 66:1275-1285
Kurella Tamura, Manjula; Vittinghoff, Eric; Hsu, Chi-Yuan et al. (2017) Loss of executive function after dialysis initiation in adults with chronic kidney disease. Kidney Int 91:948-953
Urban, Thomas Jacob; Nicoletti, Paola; Chalasani, Naga et al. (2017) Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B?35:02 as a risk factor. J Hepatol 67:137-144
Fairchild, Pamela S; Kamdar, Neil S; Rosen, Emily R et al. (2017) Ligament shortening compared to vaginal colpopexy at the time of hysterectomy for pelvic organ prolapse. Int Urogynecol J 28:899-905
Lok, A S; Ganova-Raeva, L; Cloonan, Y et al. (2017) Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment. J Viral Hepat 24:1032-1042
Djuric, Zora; Turgeon, D Kim; Sen, Ananda et al. (2017) The Anti-inflammatory Effect of Personalized Omega-3 Fatty Acid Dosing for Reducing Prostaglandin E2 in the Colonic Mucosa Is Attenuated in Obesity. Cancer Prev Res (Phila) 10:729-737

Showing the most recent 10 out of 844 publications